News, features, and commentary about cancer-related issues ...

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ... Read More The post Health Check: Telix jumps first hurdle with its ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

Investing.com-- Shares of Telix Pharmaceuticals (ASX:TLX) jumped on Tuesday after the company reported positive results from a late-stage trial of its experimental prostate cancer therapy.

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of anticoagulants, investigators found no evidence of an increase in patients’ ...

Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall ...

FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...

Oxybutynin significantly reduced hot flash frequency and severity compared with placebo among men with prostate cancer ...

The Prostate Cancer Foundation (PCF) today announced the recipients of its 2025 Challenge Awards, providing over $12 million in funding for 12 multi-institutional, cross-disciplinary research teams ...